{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:36:17Z","timestamp":1790073377811,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005874","name":"Universit\u00e0 degli Studi G. d'Annunzio Chieti - Pescara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bmc.2019.115257","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T12:19:47Z","timestamp":1575893987000},"page":"115257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors"],"prefix":"10.1016","volume":"28","author":[{"given":"Antonio","family":"Laghezza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Luisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Caradonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Pizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Loiodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Agamennone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115257_b0005","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115257_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/284067a0","article-title":"Metastatic potential correlates with enzymatic degradation of basement membrane collagen","volume":"284","author":"Liotta","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115257_b0015","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Nagase","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0020","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations.","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115257_b0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.","volume":"6","author":"Hu","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bmc.2019.115257_b0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrn1807","article-title":"Metalloproteinases: mediators of pathology and regeneration in the CNS","volume":"6","author":"Yong","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2019.115257_b0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2741\/1810","article-title":"MMPs-role in cardiovascular development and disease","volume":"11","author":"Brauer","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.bmc.2019.115257_b0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00726-010-0689-x","article-title":"Physiology and pathophysiology of matrix metalloproteases","volume":"41","author":"Klein","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.bmc.2019.115257_b0045","first-page":"908636","article-title":"Matrix metalloproteinases and their multiple roles in Alzheimer's disease","volume":"2014","author":"Wang","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bmc.2019.115257_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/chem.201805361","article-title":"Design and structural evolution of matrix metalloproteinase inhibitors","volume":"25","author":"Fischer","year":"2019","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bmc.2019.115257_b0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1158\/1535-7163.MCT-16-0315-T","article-title":"Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth","volume":"16","author":"Tauro","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2019.115257_b0060","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1021\/jm0109053","article-title":"Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID\/CPCA approach","volume":"45","author":"Terp","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0065","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.drudis.2007.06.003","article-title":"Insight into the structural determinants for selective inhibition of matrix metalloproteinases","volume":"12","author":"Pirard","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2019.115257_b0070","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/sj.bjc.6603043","article-title":"Towards third generation matrix metalloproteinase inhibitors for cancer therapy","volume":"94","author":"Overall","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2019.115257_b0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tips.2013.02.004","article-title":"Missing the target: Matrix metalloproteinase antitargets in inflammation and cancer","volume":"34","author":"Dufour","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2019.115257_b0080","first-page":"103","article-title":"Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions","volume":"1803","author":"Deryugina","year":"2010","journal-title":"BBA"},{"key":"10.1016\/j.bmc.2019.115257_b0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2091-12-38","article-title":"Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen","volume":"12","author":"Brauer","year":"2011","journal-title":"BMC Biochem"},{"key":"10.1016\/j.bmc.2019.115257_b0090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2019.115257_b0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc1821","article-title":"Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy","volume":"6","author":"Overall","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2019.115257_b0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1749-6632.1999.tb07688.x","article-title":"Preclinical and clinical studies of MMP inhibitors in cancer","volume":"878","author":"Drummond","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bmc.2019.115257_b0105","first-page":"72","article-title":"To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition","volume":"2010","author":"Jacobsen","year":"1803","journal-title":"BBA"},{"key":"10.1016\/j.bmc.2019.115257_b0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bmcl.2005.09.057","article-title":"N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: Mode of binding in a complex with MMP-8","volume":"16","author":"Campestre","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115257_b0115","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.bmc.2013.08.054","article-title":"Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors","volume":"21","author":"Tauro","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14756366.2016.1217853","article-title":"Catechol-based matrix metalloproteinase inhibitors with additional antioxidative activity","volume":"31","author":"Tauro","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0125","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2174\/1389450116666150113121733","article-title":"Phosphonate emerging Zinc binding group in matrix metalloproteinase inhibitors","volume":"16","author":"Campestre","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.bmc.2019.115257_b0130","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00706-018-2237-4","article-title":"Mimic catechins to develop selective MMP-2 inhibitors","volume":"149","author":"Di Pizio","year":"2018","journal-title":"Monatsh Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1568026615666150813150631","article-title":"Non-zinc-binding inhibitors of MMP-13: GRID-based approaches to rationalize the binding process","volume":"16","author":"Di Pizio","year":"2016","journal-title":"Curr. Topics Med. Chem."},{"key":"10.1016\/j.bmc.2019.115257_b0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chembiol.2004.11.014","article-title":"Structural basis for the highly selective inhibition of MMP-13","volume":"12","author":"Engel","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmc.2019.115257_b0145","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1016\/j.bmcl.2009.07.151","article-title":"Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors","volume":"19","author":"Heim-Riether","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115257_b0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/jm201152u","article-title":"Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis","volume":"55","author":"Gege","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0155","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/cmdc.201300278","article-title":"Strategic targeting of multiple water-mediated interactions: a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors","volume":"8","author":"Fischer","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2019.115257_b0160","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1021\/jm500981k","article-title":"Discovery of Novel, Highly Potent, and Selective Quinazoline-2-carboxamide-Based Matrix Metalloproteinase (MMP)-13 Inhibitors without a Zinc Binding Group Using a Structure-Based Design Approach","volume":"57","author":"Nara","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0165","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/jm801166j","article-title":"Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8)","volume":"52","author":"Pochetti","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0170","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1016\/j.bmcl.2005.05.079","article-title":"Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors","volume":"15","author":"Dublanchet","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115257_b0175","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1021\/jm500505f","article-title":"Targeting Matrix metalloproteinases: exploring the dynamics of the S1\u2032 pocket in the design of selective Small Molecule Inhibitors","volume":"57","author":"Fabre","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0180","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/cmdc.201300186","article-title":"Probing the S1\u2019 Site for the Identification of Non-Zinc-Binding MMP-2 Inhibitors","volume":"8","author":"Di Pizio","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2019.115257_b0185","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cmdc.201600266","article-title":"Fragment-based discovery of 5-arylisatin based inhibitors of matrix metalloprotease-2 and 13","volume":"11","author":"Agamennone","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2019.115257_b0190","doi-asserted-by":"crossref","first-page":"E1768","DOI":"10.3390\/ijms17101768","article-title":"Seeking for non-zinc-binding MMP-2 inhibitors: synthesis, biological evaluation and molecular modelling studies","volume":"17","author":"Ammazzalorso","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2019.115257_b0195","doi-asserted-by":"crossref","first-page":"e47774","DOI":"10.1371\/journal.pone.0047774","article-title":"An integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitors","volume":"7","author":"Di Pizio","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2019.115257_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1359-6446(97)01163-X","article-title":"Virtual screening - an overview","volume":"3","author":"Walters","year":"1998","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bmc.2019.115257_b0205","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.1021\/jm1008083","article-title":"Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against chlamydia pneumonia","volume":"53","author":"Keurulainen","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0210","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bmc.2019.115257_b0215","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115257_b0220","unstructured":"Schr\u00f6dinger Release, 2018-3: Maestro, Glide, LigPrep, MacroModel, Maestro, Phase, Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2019. Maestro-Desmond Interoperability Tools, Schrodinger, LLC, New York, 2018."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619314749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619314749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:05:32Z","timestamp":1760835932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619314749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0968089619314749"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115257","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115257"}}